Cargando…

An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders

INTRODUCTION: Individuals with psychotic-spectrum disorders may smoke due to the ameliorating effect of nicotine on the cognitive deficits that accompany these illnesses. Metacognitive remediation therapy (MCR) has been shown to produce improvements in cognitive functioning among individuals with ps...

Descripción completa

Detalles Bibliográficos
Autores principales: Breitborde, Nicholas J. K., Keller-Hamilton, Brittney, Moe, Aubrey M., Pine, Jacob G., Nelson, Nicholas, Weiss, David, Hogan, Tory, Quisenberry, Amanda, Teferra, Andreas, Ferketich, Amy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8337155/
https://www.ncbi.nlm.nih.gov/pubmed/34429783
http://dx.doi.org/10.1155/2021/6617716
_version_ 1783733453912539136
author Breitborde, Nicholas J. K.
Keller-Hamilton, Brittney
Moe, Aubrey M.
Pine, Jacob G.
Nelson, Nicholas
Weiss, David
Hogan, Tory
Quisenberry, Amanda
Teferra, Andreas
Ferketich, Amy K.
author_facet Breitborde, Nicholas J. K.
Keller-Hamilton, Brittney
Moe, Aubrey M.
Pine, Jacob G.
Nelson, Nicholas
Weiss, David
Hogan, Tory
Quisenberry, Amanda
Teferra, Andreas
Ferketich, Amy K.
author_sort Breitborde, Nicholas J. K.
collection PubMed
description INTRODUCTION: Individuals with psychotic-spectrum disorders may smoke due to the ameliorating effect of nicotine on the cognitive deficits that accompany these illnesses. Metacognitive remediation therapy (MCR) has been shown to produce improvements in cognitive functioning among individuals with psychotic-spectrum disorders and provides a foundation for a novel smoking cessation intervention for this population. AIMS: To complete an open investigation of pharmacotherapy and a modified version of MCR [MCR to Quit (MCR-Q)] in promoting smoking cessation among individuals with psychotic-spectrum disorders. METHODS: Forty-nine individuals with a psychotic-spectrum disorder and who currently smoke cigarettes participated in MCR-Q while also receiving evidence-based smoking cessation pharmacotherapy. Tobacco use was assessed as follows: (i) prior to MCR-Q, (ii) immediately after completing MCR-Q, and (iii) six weeks after completion of MCR-Q. RESULTS: /Findings. During participation in MCR-Q, nearly 80% of participants made a 24-hour quit attempt. Following the completion of MCR-Q, participants experienced reductions in level of nicotine dependency and exhaled carbon monoxide, with reductions in nicotine dependency sustained six weeks after completion of MCR-Q. Over the course of their participation in MCR-Q, participants reported strong therapeutic alliance with their MCR-Q therapist and high levels of intrinsic motivation with regard to completing MCR-Q exercises. CONCLUSIONS: The results from the current study suggest cautious optimism with regard to the use of MCR-Q in combination with medication for individuals with psychotic-spectrum disorders who want to quit smoking.
format Online
Article
Text
id pubmed-8337155
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-83371552021-08-23 An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders Breitborde, Nicholas J. K. Keller-Hamilton, Brittney Moe, Aubrey M. Pine, Jacob G. Nelson, Nicholas Weiss, David Hogan, Tory Quisenberry, Amanda Teferra, Andreas Ferketich, Amy K. J Smok Cessat Research Article INTRODUCTION: Individuals with psychotic-spectrum disorders may smoke due to the ameliorating effect of nicotine on the cognitive deficits that accompany these illnesses. Metacognitive remediation therapy (MCR) has been shown to produce improvements in cognitive functioning among individuals with psychotic-spectrum disorders and provides a foundation for a novel smoking cessation intervention for this population. AIMS: To complete an open investigation of pharmacotherapy and a modified version of MCR [MCR to Quit (MCR-Q)] in promoting smoking cessation among individuals with psychotic-spectrum disorders. METHODS: Forty-nine individuals with a psychotic-spectrum disorder and who currently smoke cigarettes participated in MCR-Q while also receiving evidence-based smoking cessation pharmacotherapy. Tobacco use was assessed as follows: (i) prior to MCR-Q, (ii) immediately after completing MCR-Q, and (iii) six weeks after completion of MCR-Q. RESULTS: /Findings. During participation in MCR-Q, nearly 80% of participants made a 24-hour quit attempt. Following the completion of MCR-Q, participants experienced reductions in level of nicotine dependency and exhaled carbon monoxide, with reductions in nicotine dependency sustained six weeks after completion of MCR-Q. Over the course of their participation in MCR-Q, participants reported strong therapeutic alliance with their MCR-Q therapist and high levels of intrinsic motivation with regard to completing MCR-Q exercises. CONCLUSIONS: The results from the current study suggest cautious optimism with regard to the use of MCR-Q in combination with medication for individuals with psychotic-spectrum disorders who want to quit smoking. Hindawi 2021-07-27 /pmc/articles/PMC8337155/ /pubmed/34429783 http://dx.doi.org/10.1155/2021/6617716 Text en Copyright © 2021 Nicholas J. K. Breitborde et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Breitborde, Nicholas J. K.
Keller-Hamilton, Brittney
Moe, Aubrey M.
Pine, Jacob G.
Nelson, Nicholas
Weiss, David
Hogan, Tory
Quisenberry, Amanda
Teferra, Andreas
Ferketich, Amy K.
An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders
title An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders
title_full An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders
title_fullStr An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders
title_full_unstemmed An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders
title_short An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders
title_sort open trial of metacognitive remediation therapy and pharmacotherapy to promote smoking cessation among individuals with psychotic-spectrum disorders
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8337155/
https://www.ncbi.nlm.nih.gov/pubmed/34429783
http://dx.doi.org/10.1155/2021/6617716
work_keys_str_mv AT breitbordenicholasjk anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT kellerhamiltonbrittney anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT moeaubreym anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT pinejacobg anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT nelsonnicholas anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT weissdavid anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT hogantory anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT quisenberryamanda anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT teferraandreas anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT ferketichamyk anopentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT breitbordenicholasjk opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT kellerhamiltonbrittney opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT moeaubreym opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT pinejacobg opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT nelsonnicholas opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT weissdavid opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT hogantory opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT quisenberryamanda opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT teferraandreas opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders
AT ferketichamyk opentrialofmetacognitiveremediationtherapyandpharmacotherapytopromotesmokingcessationamongindividualswithpsychoticspectrumdisorders